Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
+$0.05 today
- Market cap
- $196.25M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
Volume 0.23M
Average 0.32M
GALT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Galectin Therapeutics Inc.NASDAQ: GALT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$3.05M, compared with -$7.88M a year earlier. Trailing-twelve-month EBITDA was -$18.62M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +43.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$3.05M+13.5% QoQ
- Last fiscal yearDec 2025
- -$23.45M+43.4% YoY
- LTMMar 2026
- -$18.62M+52.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +61.3% | +100.0% | +38.7 pp |
| 1 year | +43.4% | +100.0% | +56.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (23.45M) USD
- Year-over-year change
- +43.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (23.45M) | +43.4% |
| FY2024 | 2024-12-31 | (41.47M) | -8.4% |
| FY2023 | 2023-12-31 | (38.24M) | -1.4% |
| FY2022 | 2022-12-31 | (37.71M) | -25.7% |
| FY2021 | 2021-12-31 | (30M) | — |
EBITDA vs competitors
How GALT compares with its peers on the latest reported figures
- GALT's LTM Mar 2026 EBITDA of -$18.62M is the highest of the 10 companies compared; the peer median is -$88.27M.
- Its year-over-year change of +52.1% is the highest of 9, against a peer median of -21.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$18.62M | +52.1% | — | — | |
| LTM Mar 2026 | -$35.03M | -30.1% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.05M | — | — | — |
| LTM Mar 2026 | -$44.93M | -42.6% | — | — | |
| LTM Mar 2026 | -$69.09M | -24.3% | — | — | |
| LTM Mar 2026 | -$88.27M | +2.7% | — | 245200.0% | |
| LTM Mar 2026 | -$99.13M | -3.1% | — | 5352.8% | |
| LTM Mar 2026 | -$111.17M | -19.0% | — | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$125.94M | -65.1% | — | — |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
| Peer median (excluding GALT) | -$88.27M | -21.7% | — | 125276.4% | |
Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.82M | 31.74M | 32.13M | 36.57M | 14.29M |
| Selling, General & Admin | 6.36M | 6.62M | 5.94M | 5.86M | 5.8M |
| Operating Expenses | 30.18M | 38.35M | 38.07M | 42.43M | 20.09M |
| Depreciation & Amortization | 41K | 32K | 33K | 37K | 53K |
| EBITDA | (30M) | (37.71M) | (38.24M) | (41.47M) | (23.45M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (30.18M) | (38.35M) | (38.07M) | (42.43M) | (20.09M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3K | 52K | 230K | 338K | 126K |
| Interest Expense | 489K | 1.03M | 2.79M | 5.54M | 7.33M |
| Other Income / Expenses | (348K) | (424K) | (2.99M) | (4.61M) | (10.75M) |
| Income Before Tax | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| EPS (Diluted) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| Weighted Avg Shares | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
| Weighted Avg Shares (Diluted) | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
Galectin Therapeutics Inc.
NASDAQ:GALT
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.